openPR Logo
Press release

Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024 Report

05-04-2018 11:52 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Tumor Necrosis Factor Inhibitors Drug Market Dosage

“Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024” Report Highlights:

* Global TNF Inhibitors Market Trends
* Key TNF Inhibitors Drug Sales, Price and Dosage Analysis
* Global TNF Inhibitors Clinical Pipeline by Company, Indication and Phase
* Sales Projections of Key Drugs Till 2024
* Clinical Pipeline Data by Phase
* TNF Inhibitors Market Future Outlook
* Marketed Drug Clinical and Patent Insight

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-tumor-necrosis-factor-inhibitors-drug-market-dosage-price-and-clinical-pipeline-outlook-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Tumor Necrosis Factor andndash; An Overview
1.1 Prologue to Tumor Necrosis Factor
1.2 History and Discovery of Tumor Necrosis Factors

2. Significance of Tumor Necrosis Factor
2.1 TNF in Cell Signalling and Immunity
2.1.1 Tumor Necrosis Factor Receptor 1
2.1.2 Tumor Necrosis Factor Receptor 2
2.2 Role of TNF in Cancer
2.3 Disease Related to TNF and Members of Its Family

3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors and Their Therapeutic Evolution
3.1 Tumor Necrosis Factor and Immune Response
3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies

4. Approaches Used in Development of TNF Inhibitors
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview

6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication and Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered

7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company and Indication
7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony and Symposony)
7.2 Pomalidomide (Imnovid and Pomalyst)
7.3 Adalimumab (Humira and Raheara)
7.4 Infliximab (Remicade)
7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia and Simziya)
7.6 Apremilast (Otezla)
7.7 Infliximab Biosimilar - Celltrion
7.8 Lumbricus Rubellus Extract (Inflectra and Remsima)
7.9 Adalimumab Biosimilar (AdaliRel and Adfrar)
7.10 Infliximab Biosimilar (Infimab)
7.11 Infliximab Biosimilar - Bionovis/ The Instituto Vital Brazil
7.12 Adalimumab Biosimilar (Exemptia)
7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral

8. Price, Dosage and Treatment Cost Analysis of Commercially Available TNF Based Therapeutics
8.1 Cimzia (Certolizumab Pegol)
8.2 Enbrel (Etanercept)
8.2.1 Benepali andndash; Etanercept Biosimilar
8.3 Humira ( Adalimumab)
8.3.1 Amjevita andndash; Humira Biosimilar
8.3.2 Cyltezo andndash; Second Biosimilar to Humira
8.4 Otezla (Apremilast)
8.5 Remicade (Infliximab)
8.5.1 Remsima - Infliximab Biosimilar
8.5.2 Inflectra andndash; Infliximab Biosimilar
8.6 Simponi (Golimumab)

9. Current Market Trends and Recent Advances in the TNF Inhibitors Segment
9.1 Dominance of TNF Inhibitors in Global Therapeutics Market
9.2 Global TNF Inhibitor Market by Indication andndash; Market Size and Growing Opportunity
9.2.1 Rheumatoid Arthritis
9.2.2 Psoriasis and psoriatic arthritis (PsA)
9.2.3 Crohn’s Disease
9.2.4 Ankylosing Spondylitis
9.3 Global TNF Inhibitors Market by Region
9.3.1 US
9.3.2 Europe
9.3.3 Asia- Pacific
9.3.4 Middle East and Africa (MEA)

10. TNF Inhibitor- Sales and Patent Analysis
10.1 TNF Inhibitor Market by Sales
10.1.1 Cimzia
10.1.2 Enbrel
10.1.3 Humira
10.1.4 Remicade
10.2 TNF Inhibitor Market by Approvals and Patent
10.3 TNF Inhibitor Biosimilar Sales Analysis

11. TNF Inhibitors Market Driving Parameters

12. Restraining Factors of the Global TNF Inhibitors Market

13. Global andndash; TNF Inhibitors Future Forecast and Sales Projections
13.1 Impact of Biosimilar ‘Benepali’ on Enbrel Sales
13.2 Affordable Alternatives to Humira and Their Effect on Global Humira Sales
13.3 Remicade and Its Biosimilar
13.4 Conclusion and Executive Summary

14. Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

Figure 1-1: Multiple Roles of TNF
Figure 1-2: Historical timeline of Tumor Necrosis Factor
Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors
Figure 2-1: TNF Factor Types and Their Inhibition
Figure 2-2: Diseases Related to TNF and Its Family Members
Figure 3-1: General Working Mechanism of TNF Inhibitors
Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%),2018 till 2024
Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 8-1: Cimzia - Dose for Crohn's Disease (mg/week)
Figure 8-2: Cimzia - Dose for Rheumatoid Arthritis (US$)
Figure 8-3: Cimzia - Dose for Psoriatic Arthritis (mg)
Figure 8-4: Cimzia - Dose for Ankolysing Spondylitis (mg)
Figure 8-5: Cimzia (Certolizumab Pegol) andndash; Average Price (US$)
Figure 8-6: Cimzia - Treatment Cost Analysis, 2018
Figure 8-7: TNF inhibition by Enbrel, Working Mechanism
Figure 8-8: Enbrel - Dosage Forms and Strength (mg and ml)
Figure 8-9: Enbrel - Dosage and Frequency for Arthritis, AS and PsA (mg/Week)
Figure 8-10: Enbrel - Dose for Juvenile Idiopathic Arthritis (mg and mg/kg)
Figure 8-11: Enbrel - Subcutaneous Kit Price (US$/Unit), 2018
Figure 8-12: Enbrel - Prefilled Syringe Price (US$/Vial), 2018
Figure 8-13: Global - Enbrel Price by Region (US$)
Figure 8-14: Enbrel - Treatment Cost Analysis (US$/Month)
Figure 8-15: Enbrel - Price per QALY Gained (US$), 2018
Figure 8-16: Humira - Mechanism of Action
Figure 8-17: Humira - Dosage Analysis by Indication (mg)
Figure 8-18: Humira - Dosage Analysis for Crohn's Disease (mg)
Figure 8-19: Humira - Dose for Plaque Psoriasis (mg)
Figure 8-20: Humira - Subcutaneous Kit Price (US$), 2017
Figure 8-21: Humira - Average Treatment Cost Analysis per Month (US$), 2017
Figure 8-22: Otezla - Dose for Plaque Psoriasis
Figure 8-23: Otezla - Price Analysis (US$/Unit), 2017
Figure 8-24: Remicade (Infliximab)- Mode of Action
Figure 8-25: Remicade - Dose for Crohn's Disease (mg/kg)
Figure 8-26: Remicade - Dose for Rheumatoid Arthritis (mg/kg)
Figure 8-27: Remicade- Price Analysis for 100mg Vial (US$), 2018
Figure 8-28: Simponi - Availability by Concentration (mg/0.5ml)
Figure 8-29: Simponi - Dosage Analysis (mg)
Figure 8-30: Simponi - Price Analysis (US$/ml), 2018
Figure 9-1: Global- Therapeutics Market Segmentation by size (%)
Figure 9-2: Global - Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017
Figure 9-3: Global - Psoriasis and Psoriatic Arthritis Prevalence, 2015-2016
Figure 9-4: Global- Crohn's Disease Epidemiology (per 100,000 Individuals), 2012-2017
Figure 9-5: Global - Ankylosing Spondylitis (per 100,000 Individuals), 2018
Figure 9-6: US - TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017
Figure 9-7: Humira Cost Analysis by Region- US v/s India (US$/Vial), 2017
Figure 10-1: Global- Cimzia Sales (US$ Million), 2016 and 2017
Figure 10-2: Global - Enbrel Sales (US$ Million), 2014-2017
Figure 10-3: Global- Humira Sales (US$ Million), 2014-2017
Figure 10-4: Global- Remicade Sales (US$ Million), 2014-2017
Figure 10-5: Global - TNF Inhibitors Patent by Number
Figure 10-6: Patent Analysis - Patent Expiration by Year
Figure 10-7: Global - TNF Inhibitor Biosimilar Sales (US$ Million), 2015-2017
Figure 10-8: Global - Benepali Sales (US$ Million), 2016-2017
Figure 11-1: Driving Factors of the TNF Inhibitors Segment
Figure 12-1: Challenging Factors of the TNF Inhibitors Market
Figure 13-1: Global - Enbrel Sales Future Forecast (US$ Million), 2017-2024
Figure 13-2: Global - Humira Sales Forecast (US$ Million), 2017-2024
Figure 13-3: Global - Amjevita Sales Future Forecast (US$ Million), 2020 and 2024
Figure 13-4: Global - Remicade Future Sales Forecast (US$ Million), 2016-2024
Figure 13-5: Global - Blockbuster TNF Inhibitors Sales (US$ Billion), 2017
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024 Report here

News-ID: 1039534 • Views: 365

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Figure

THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Global Leisure Boats Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Leisure Boats Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Leisure Boats in Global market,especially in North America,China,Europe,Southeast Asia,Japan and India,with production,revenue,consumption,import and export in these regions,from 2013 to 2018,and forecast to 2025. This report focuses on top manufacturers in global market,with production,price,revenue and market share for each manufacturer,covering Riva Sunseeker Ferretti Lurssen Azimut Wally Princess Pershing Free Sample of this report is available upon request @
Global Protective Packaging Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Protective Packaging Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Protective Packaging in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and
Lawn Mower Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report 2018-2025 Lawn Mower Report on Global and United States Market, Status and Forecast, by Players, Types and Applications to its huge collection of research reports. This report studies the Lawn Mower market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the
Glissandra Skincare Proudly Supports World Figure Skating Champion, Patrick Chan
Glissandra Skincare is honoured to have participated in the World Chinese Business Association of Canada’s 2012 Fundraising Dinner to support Patrick Chan. Vancouver, BC, Canada, February 21, 2012 -- On Saturday, February 18, 2012, hundreds of guests packed the Victoria Chinese Restaurant in Downtown Vancouver to celebrate Canadian figure skater, Patrick Chan. The event was hosted by the World Chinese Business Association of Canada and raised almost $60,000 to assist in
Personal injury solicitors help client to reach five-figure settlement
Fentons Solicitors LLP, one of the UK's leading personal injury solicitors, has achieved a five-figure settlement victory for a client that suffered multiple severe injuries when the car he was a passenger in struck a line of parked cars. The 48-year old former hod-carrier was a front seat passenger when the driver lost control of the car and collided with a number of stationary vehicles. Fentons helped him to reach an